IRIS
COSTANZO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.268
EU - Europa 2.396
AS - Asia 1.259
SA - Sud America 27
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 10
AF - Africa 3
Totale 21.974
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.247
SG - Singapore 516
CN - Cina 471
UA - Ucraina 427
DE - Germania 393
SE - Svezia 263
IE - Irlanda 256
IT - Italia 198
RU - Federazione Russa 195
PL - Polonia 173
FR - Francia 169
GB - Regno Unito 166
HK - Hong Kong 96
FI - Finlandia 87
KR - Corea 81
BE - Belgio 24
BR - Brasile 18
CA - Canada 18
IN - India 18
JP - Giappone 17
IL - Israele 11
KG - Kirghizistan 11
AU - Australia 10
NL - Olanda 9
UZ - Uzbekistan 9
EU - Europa 8
CH - Svizzera 7
ES - Italia 5
VN - Vietnam 5
CL - Cile 4
PK - Pakistan 4
RO - Romania 4
AT - Austria 3
DK - Danimarca 3
GR - Grecia 3
IR - Iran 3
MY - Malesia 3
AR - Argentina 2
BD - Bangladesh 2
HR - Croazia 2
ID - Indonesia 2
MX - Messico 2
NO - Norvegia 2
PH - Filippine 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
CO - Colombia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
SC - Seychelles 1
TR - Turchia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 21.974
Salva come PNG Salva come JPEG
Città #
Woodbridge 4.873
Wilmington 3.992
Houston 3.517
Ann Arbor 900
Fairfield 815
Chandler 638
Ashburn 481
Singapore 427
Seattle 396
Jacksonville 393
Cambridge 293
Dublin 254
Medford 221
Beijing 186
Dearborn 179
Kraków 170
New York 115
Lawrence 103
Hong Kong 90
Santa Clara 90
Zhengzhou 84
Mülheim 67
Boardman 54
San Diego 49
Menlo Park 43
Moscow 40
Rome 34
San Mateo 34
Falls Church 31
Shanghai 28
Milan 27
Brussels 24
Munich 23
Redwood City 21
Saint Petersburg 17
Hefei 16
Mountain View 16
London 15
University Park 15
Jinan 11
Kunming 11
Nanjing 11
Norwalk 11
Auburn Hills 10
Guangzhou 10
Toronto 10
Hangzhou 9
Perugia 9
Nürnberg 8
Pune 8
Verona 8
Saint Louis 7
Wuhan 7
Changsha 6
Chicago 6
Detroit 6
Nuremberg 6
Chengdu 5
Clearwater 5
Los Angeles 5
Nanchang 5
Shenyang 5
São Paulo 5
The Dalles 5
Bern 4
Hebei 4
Helsinki 4
High Wycombe 4
Hounslow 4
Palo Alto 4
Trani 4
Amsterdam 3
Berlin 3
Calgary 3
Casarile 3
Chiyoda-ku 3
Cremona 3
Espoo 3
Fuzhou 3
Hanoi 3
Kuala Lumpur 3
Madrid 3
Manchester 3
Nijmegen 3
Phoenix 3
Redmond 3
San Francisco 3
Shenzhen 3
Tappahannock 3
Tokyo 3
Wenzhou 3
Ypsilanti 3
Bangalore 2
Baoding 2
Bari 2
Bethesda 2
Cagliari 2
Campinas 2
Chaoyang 2
Chongqing 2
Totale 19.067
Salva come PNG Salva come JPEG
Nome #
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 465
The p53/p63/p73 family of transcription factors: overlapping and distinct functions 455
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 442
Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis 440
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage 439
Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients 438
Induction of gene expression via activator protein-1 in the ascorbate protection against UV-induced damage 423
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 420
IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN- -Dependent Epidermal Hyperplasia 420
Actinic keratosis treated with an immune response modifier: a case report of six patients 412
Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: Implications for the cellular response to DNA damage 412
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 411
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target 401
Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population 395
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage 394
Structure, function and regulation of p63 and p73 391
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 391
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 384
Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases 384
IL-21 in the pathogenesis and treatment of skin diseases 383
PSORS2 markers are not associated with psoriatic arthritis in the Italian population 382
Herpes simplex virus disrupts NF-kappa B regulation by blocking its recruitment on the I kappa B alpha promoter and directing the factor on viral genes. 375
Pathogenic role of interleukin-21 in psoriasis 371
Induction of neuronal differentiation by p73 in a neuroblastoma cell line 370
Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain 368
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 365
The tumor suppressor activity of IKK alpha in stratified epithelia is exerted in part via the TGF-beta anti proliferative pathway 362
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 362
Elementi di dermatologia 357
Zosteriform metastasis of occult bronchogenic carcinoma 353
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 349
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene 337
Two new p73 splice variants, gamma and delta, with different transcriptional activity 332
Zosteriform metastasis of occult bronchogenic carcinoma 332
Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis 329
Psoriasis: from pathogenesis to novel therapeutic approaches 321
Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants  and  312
High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis 302
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 301
Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model 299
IL-21, a new player in pathogenesis of psoriasis 298
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 277
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 222
Treatment of vitiligo with the 308 nm excimer laser 175
Claudin-1 is a p63 target gene with a crucial role in epithelial development 161
A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias 155
Treasure or artifact: a decade of p63 research speaks for itself 148
308 nm monochromatic excimer light in the treatment of psoriasis 143
Different applications of monochromatic excimer light in skin diseases 141
p63 and p73 transactivate differentiation gene promoters in human keratinocytes 141
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 140
Safety and efficacy study on etanercept in patients with plaque psoriasis 139
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers 135
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways 135
Moderate and severe plaque psoriasis: Cost-of-illness study in Italy 132
A feedback regulatory loop between p63 and Dlx3: implications for epidermal differentiation 130
Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides 129
p63 induces key target genes required for epidermal morphogenesis 128
Cross-talks in the p53 family - Delta Np63 is an anti-apoptotci target for Delta Np73 alpha and p53 gain-of-function mutants 124
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience 123
A role of p73 in mitotic exit 122
Consecutive use of different biological therapies in the treatment of psoriasis [4] 122
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells 120
DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes 119
Regulation of Dlx5 and Dlx6 gene expression by p63 is involved in EEC and SHFM congenital limb defects 117
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 117
Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells 114
Safety and efficacy study on etanercept in patients with plaque psoriasis 112
Homeobox gene Dlx3 is regulated by p63 during ectoderm development: relevance in the pathogenesis of ectodermal dysplasias 112
NF-κB, IκB Kinase and Interacting Signal Networks in Squamous Cell Carcinomas 112
p73 is regulated by phosphorylation at the G2/M transition 111
Differential regulation of E2F1 apoptotic target genes in response to DNA damage 111
RelA/NF-kappa B recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells 110
The p73 gene is an anti-tumoral target of the RAR beta/gamma-selective retinoid tazarotene 109
CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters 109
deltaEF1 repressor controls selectively p53 family members during differentiation 107
Pharmacological treatment of androgenetic alopecia.Result of an observational study 104
Etanercept for the treatment of severe childhood psoriasis [3] 103
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting 103
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 101
Efalizumab 100
Efficacy and safety of etanercept in psoriasis after switching from other treatments: An observational study 99
A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes 98
CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappa B subunits on IL-8 and Bcl-xL gene promotors 96
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab 89
Etanercept reverses downregulation of inhibitor of nuclear factor kappa-B kinase subunit alpha (IKKa) in psoriasis 85
Delta Np63 Knockdown Mice: A Mouse Model for AEC Syndrome 83
Pharmacogenomics: getting closer to a tailored therapy? 81
DNp73 alpha protects myogenic cells from apoptosis 81
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 75
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 74
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 69
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis 63
Keratosis punctata palmoplantaris and malignancies: case report 59
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 57
Label-free and non-invasive discrimination of HaCaT and melanoma cells in a co-culture model by hyperspectral confocal reflectance microscopy 55
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 53
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 50
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 48
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 47
Totale 22.052
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.158
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.158
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.339 0 0 0 0 0 626 521 529 486 518 295 364
2020/20213.037 287 372 322 354 240 279 352 271 144 117 224 75
2021/20221.147 36 91 111 63 29 116 44 60 83 122 60 332
2022/20231.530 167 132 84 246 136 315 84 75 153 6 97 35
2023/2024521 74 18 29 19 43 140 21 68 3 5 6 95
2024/20251.095 115 420 215 157 38 150 0 0 0 0 0 0
Totale 22.202